Navigation Links
Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
Date:6/12/2012

SAN DIEGO and RALEIGH-DURHAM, N.C., June 12, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), will unveil its new branding at this year's Drug Information Association (DIA) annual meeting to be held from June 24-28 in Philadelphia at the Pennsylvania Convention Center. Synteract will exhibit in booth #1925. The company has revamped its brand to better showcase the full range of Phase I-IV services and expertise it offers biotechnology, medical device, and pharmaceutical companies.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

While the company's tagline – Shared Work-Shared Vision™ – has not changed, it has been enhanced by additional messaging that helps to define Synteract's updated commercial strategy and strong partnership approach. The company has evolved and expanded its service offering, scale and reach in response to client demand. The new brand platform serves to reinforce that updated perspective on Synteract to the industry. The company used images of its own people in its marketing because they are the cornerstone of the global clinical development and industry expertise supporting clients every day. 

The company's continued growth on the East Coast in Research Triangle Park and in Europe has been a driver for the revamped brand identity, according to Synteract CEO Wendel Barr. "Our updated brand position reflects the evolution and growth Synteract has achieved through our commitment to serving the unique needs of emerging to midsize biotech and pharma. Our high rate of repeat business is a testament to our success, as is our support of 22 product approvals. It's the commitment of our employees that has sustained our growth as well as that of our clients. Our continued dedication to great partnerships will be more clearly communicated through this revised messaging and strong visual identity that focuses on our people – they are Synteract."

As part of its strategy, the company is hiring to augment its medical, clinical, biostatistics and regulatory expertise and has increased its sales and marketing investment as well. The refocused brand identity includes a fully revamped website and tradeshow booths, increased advertising, public relations and social media efforts. Synteract's leaders are actively engaged in front of the medical, scientific and business communities through speaking engagements, contributed articles and interaction with industry associations and standards bodies such as CDISC, SCDM, DIA and others.

Barr added, "The new brand platform allows Synteract to more clearly address our differentiators within this competitive industry, giving current and prospective clients an overview of our customized approach and longstanding clinical development experience to facilitate their search for an outsourcing partner to match their specific needs. And as we move forward with European acquisition plans later this year, we want our culture to be clear."

At DIA, Synteract's growing team of drug development experts will be available to discuss the company's clinical development expertise. To set up an appointment in advance, contact Matt Smith, SVP Sales and Marketing at 760-795-2149 or msmith@synteract.com. The company will also host a reception at its booth on Monday, June 25th, 4:00 p.m.

About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development.  With its "Shared Work – Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology. 

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424


'/>"/>
SOURCE Synteract, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference
2. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
3. SPYru™ unveils "The Uberwater"
4. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
5. MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference
6. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
7. Fluke Biomedical training center goes global: adds multi-language support
8. MDA Supports Development of Dissociative Glucocorticoid for DMD
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
11. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):